Send Us A Message

Have questions for us? Contact us to find out more.

Hematologic Malignancies

April 12, 2019

  • Vanda-VTR-297-1101-A Phase I multicenter, open label, dose-escalation study to determine the maximum tolerated does for Trichostatin A in subjects with replapsed or refractory Hematologic Malignancies.
  • Adagene Inc.-ADG106-A Study of CD137 Agonist ADG106 Administered Intravenously in Patients with Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma